Real World Assessment of Once-a-Month Dosing of Lebrikizumab in Commercial Claims. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 10, n. 2, p. s747, 2026. DOI: 10.25251/6b1dka07. Disponível em: https://skin.dermsquared.com/skin/article/view/4118. Acesso em: 30 apr. 2026.